For Medicare beneficiaries, expanded formulary inclusion or negotiation windows may lead to notably lower co-pays during the rollout, while Medicaid changes will vary by state and reflect local adoption timelines and preferred drug lists
Nausea affects between 25% and 44% of people taking these medications, making it the most common side effect
decreased smooth muscle cell proliferation reduces neointimal formation Anti-inflammatory signaling: Suppression of NF-kB, reduced macrophage infiltration into plaques, and decreased secretion of IL-6, TNF-alpha, and MCP-1 from monocytes and foam cells Atherogenic lipid reduction: Improvements in LDL cholesterol, VLDL, triglycerides, and chylomicron remnants beyond what weight loss alone would predict Blood pressure reduction: Through direct vasodilation and natriuresis, independent of weight change Epicardial and perivascular fat reduction: This fat depot exerts direct paracrine inflammatory effects on the vascular endothelium and myocardium
In March of this year, Wegovy was approved for overweight or obese patients with cardiovascular disease